

biogen idec

June 23, 2008

Center for Drug Evaluation and Research
Food and Drug Administration
5901 -B Ammendale Rd
Beltsville, MD 20705-1 266

Attn: Russell Katz, MD

**RE: IND 73,061: BG00012 (Dimethyl Fumarate): Multiple Sclerosis
Information Amendment: Study C-1900 - Clinical Study Report
Serial No.: 0060**

Dear Dr. Katz:

Biogen Idec, Inc. is submitting the final clinical study report for a Phase 2 study (C-1900), entitled:

"A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis".

[REDACTED]

Should you require any additional information, please contact Tammy Sarnelli, Director, Regulatory Affairs, at 617-679-3513. The contact for technical aspects for this submission is [REDACTED] Senior Director, Regulatory Affairs Operations, at 617-679-2416.

Sincerely:

[REDACTED]

Senior Vice President, Regulatory Affairs
Phone: (617) 679-3783
Fax: (617) 679-3170

Biogen Idec 14 Cambridge Center, Cambridge, MA 02142 Phone 617 679 2000 www.biogenidec.com